APA (7th ed.) Citation

ES, T., MS, D., R, P., S, T., J, G., L, W., . . . P, M. (2024). Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO precision oncology, 8, e2300494. https://doi.org/10.1200/PO.23.00494

Chicago Style (17th ed.) Citation

ES, Tsang, et al. "Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2." JCO Precision Oncology 8 (2024): e2300494. https://doi.org/10.1200/PO.23.00494.

MLA (9th ed.) Citation

ES, Tsang, et al. "Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2." JCO Precision Oncology, vol. 8, 2024, p. e2300494, https://doi.org/10.1200/PO.23.00494.